Back to results
US 2004/0176573 A1Published application
Survivin-derived peptides and use thereof
AssigneeBioVision A/S
InventorsEivind Per Thor, Mads Hald
Life of this patent
Estimating the term…
Abstract
MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses hereof.
Claims49
A MHC Class I-restricted epitope peptide derived from survivin, said epitope having at least one of the following characteristics:
- (i) capable of binding to the Class I HLA molecule to which it is restricted at an affinity as measured by the amount of the peptide that is capable of half maximal recovery of the Class I HLA molecule (C50 value) which is at the most 50 μM as determined by the assembly binding assay as described herein,
- (ii) capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient at a frequency of at least 1 per 104 PBLs as determined by an ELISPOT assay, and/or
- (iii) capable of in situ detection in a tumor tissue of CTLs that are reactive with the epitope peptide.
A peptide according to any of the preceding claims, which is phosphorylated.
Dependencies are inferred from the claim text.